6
25M
4
0.38
1
0.33
2
- Areas of investment
Summary
In 2005 was created CVF, which is appeared as Corporate Investor. The company was established in North America in United States. The main office of represented Corporate Investor is situated in the Davis.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Sonendo, Cerulean Pharma Among the most successful fund investment fields, there are Nanotechnology, Biotechnology.
The increased amount of exits for fund were in 2014. Speaking about the real fund results, this Corporate Investor is 20 percentage points more often commits exit comparing to other organizations. The fund is constantly included in less than 2 investment rounds annually. The important activity for fund was in 2016. Opposing the other organizations, this CVF works on 9 percentage points less the average amount of lead investments. The common things for fund are deals in the range of 10 - 50 millions dollars.
The typical case for the fund is to invest in rounds with 6-7 participants. Despite the CVF, startups are often financed by OrbiMed, Neomed Management, Fjord Ventures. The meaningful sponsors for the fund in investment in the same round are OrbiMed, Venrock, Polaris Partners. In the next rounds fund is usually obtained by Venrock, Polaris Partners, OrbiMed.
Investments analytics
Analytics
- Total investments
- 6
- Lead investments
- 1
- Exits
- 2
- Rounds per year
- 0.38
- Follow on index
- 0.33
- Investments by industry
- Biotechnology (6)
- Health Care (4)
- Medical (3)
- Nanotechnology (2)
- Therapeutics (2) Show 5 more
- Investments by region
-
- United States (6)
- Peak activity year
- 2012
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 17
- Group Appearance index
- 1.00
- Avg. company exit year
- 11
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Genocea Biosciences | 10 Oct 2012 | Biotechnology, Medical | Late Stage Venture | 30M | United States, Cambridge, Massachusetts |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.